Nuvectis Raises Funds Again as Oncology and Immunology Pipeline Enters a Capital Test Period
Not long after acquiring new clinical assets, Nuvectis is seeking to replenish capital, underscoring how, when small biotech companies advance cancer and immunotherapy programs, the scientific narrative quickly returns to cash, trial cadence, and the maturity of evidence.